Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

NCT07340216 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: ARQ-154 Foam 0.3%

Sponsor

Arcutis Biotherapeutics, Inc.